Dear Partners,

We are delighted to share with you the latest Slenyto® news as part of our common efforts towards a successful launch;

Slenyto® Brand Meeting

We would like to thank our partners for your attendance to Slenyto® Brand Meeting which was successfully held in Rotterdam on May 9th. 24 attendees from 8 countries attended the meeting. During the meeting the attendees were provided with the recent clinical updates, summary and insights from first global advisory board, updates on global brand plan and conclusions from launch campaign testing including introduction of final launch campaign and visuals.







INSAR 2018

Neurim Pharmaceuticals supported INSAR 2018 Annual Meeting in Rotterdam. The congress attendees, among them global and local ASD experts, were introduced to Slenyto® clinical trial results (3 and 6 months) via our medical information booth and to the 12 months results at the scientific presentation given by Dr. Athanasios Maras from the Netherlands as part of the “Pharmacological Interventions in ASD and Related Conditions” scientific session.

Upcoming events:

  • IACAPAP 2018- 23rd World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions will be held on 17-23 July 2018 in Prague, Czech Republic. For the first time, the implications of Slenyto® on child behavior and parents’ quality of life will be presented as part of the scientific program of the congress by Dr. Athanasios Maras, “Pediatric prolonged-release melatonin for sleep in children with Autism Spectrum Disorder: Implications for child behavior and caregiver’s quality of life” (date and time TBD).

Looking forward to continuing introduction of Slenyto® to the local markets and see you and your clients participating in further International events!

  • Text size: A A A
  • Circadin
  • Recent news

    • Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018
    • Neurim sponsors a Satellite Symposium “Navigating through the Insomnia Roadmap in Children with ASD” at IPSA 2018, Paris, France.
    • Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by BIOCODEX Oy in Finland
  • Partners